The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/Ib multicenter study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent, in combination with CPI-444, and in combination with pembrolizumab in adult patients with advanced cancers.
 
Mehrdad Mobasher
Employment - Corvus Pharmaceuticals; Genentech
Leadership - Corvus Pharmaceuticals
Stock and Other Ownership Interests - Corvus Pharmaceuticals; Roche
Research Funding - Corvus Pharmaceuticals; Genentech
Travel, Accommodations, Expenses - Corvus Pharmaceuticals; Genentech
 
Richard A. Miller
Employment - Corvus Pharmaceuticals; Roche/Genentech (I)
Leadership - Corvus Pharmaceuticals; Genentech/Roche (I)
Stock and Other Ownership Interests - Bolt Biotherapeutics; Corvus Pharmaceuticals; Genentech/Roche (I)
Patents, Royalties, Other Intellectual Property - Inventor on patent application dealing with Corvus product under development
 
Long Kwei
Employment - Corvus Pharmaceuticals
Leadership - Corvus Pharmaceuticals
Stock and Other Ownership Interests - Corvus Pharmaceuticals
 
Deborah Strahs
Employment - Corvus Pharmaceuticals
Stock and Other Ownership Interests - Merck; Pfizer
 
Vaijayanti Das
Employment - Corvus Pharmaceuticals
 
Gabriel Luciano
Employment - Corvus Pharmaceuticals
Leadership - Corvus Pharmaceuticals
Stock and Other Ownership Interests - Corvus Pharmaceuticals
Consulting or Advisory Role - Corvus Pharmaceuticals
 
John D. Powderly
Employment - BioCytics; Carolina BioOncology Institute
Leadership - BioCytics; Carolina BioOncology Institute
Stock and Other Ownership Interests - BioCytics; Bluebird Bio; Carolina BioOncology Institute; Juno Therapeutics; Kite, a Gilead company; Lion Biotechnologies; ZIOPHARM Oncology
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Curis; Genentech/Roche; TopAlliance BioSciences Inc
Speakers' Bureau - Bristol-Myers Squibb; Dendreon; Genentech/Roche; Merck
Research Funding - Abbvie; Alkermes; Arcus Biosciences; AstraZeneca/MedImmune; Bristol-Myers Squibb; Corvus Pharmaceuticals; Curis; EMD Serono; FLX Bio; Genentech/Roche; Incyte; Lilly/ImClone; Macrogenics; Seagen; Tempest Therapeutics; Top Alliance BioScience
Patents, Royalties, Other Intellectual Property - BioCytics is developing intellectual property for cellular immunotherapy
Other Relationship - Ongoing discussions with potential future biopharma and biotech for Human Applications Lab sponsored projects
 
Jaime R. Merchan
Consulting or Advisory Role - Etelitis
Research Funding - Astellas Pharma (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Genentech (Inst); Lilly (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Replimune (Inst); Rexahn Pharmaceuticals (Inst); Seagen (Inst); Sillajen (Inst); Tocagen (Inst); Vyriad (Inst)
 
Minal A. Barve
No Relationships to Disclose
 
Patricia LoRusso
Consulting or Advisory Role - Alexion Pharmaceuticals; ARIAD; Chiltern; CytomX Therapeutics; Five Prime Therapeutics; Genentech; Genmab; Glenmark; Halozyme; Ignyta; Menarini; Novartis; Novella Clinical; Omniox; Roche/Genentech; Takeda
Research Funding - Alexion Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Genentech (Inst); Immunogen (Inst); Merrimack (Inst); Novartis (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Tensha Therapeutics (Inst)
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; Genentech/Roche
 
Abhishek Tripathi
Research Funding - Bayer (Inst); Clovis Oncology (Inst); Corvus Pharmaceuticals (Inst)
 
Jason J. Luke
Stock and Other Ownership Interests - Actym Therapeutics
Consulting or Advisory Role - 7 Hills Pharma; Actym Therapeutics; Aduro Biotech; Alphamab; Amgen; Array BioPharma; AstraZeneca/MedImmune; Benevir; Bristol-Myers Squibb; Castle Biosciences; Checkmate Pharmaceuticals; Compugen; EMD Serono; Gilead Sciences; IDEAYA Biosciences; Janssen; Jounce Therapeutics; Mavu Pharmaceutical; Merck; Newlink Genetics; Novartis; Reflexion Medical; Spring Bank; Syndax; Tempest Therapeutics; TTC Oncology; Vividion Therapeutics; WntRx Pharmaceuticals
Research Funding - Abbvie (Inst); Array BioPharma; Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Checkmate Pharmaceuticals; Compugen (Inst); Corvus Pharmaceuticals (Inst); Delcath Systems (Inst); Evelo Therapeutics; Five Prime Therapeutics (Inst); FLX Bio; Genentech/Roche (Inst); Immunocore (Inst); Incyte (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Palleon Pharmaceuticals; Pharmacyclics (Inst); Tesaro (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Serial #15/612,657 (Cancer Immunotherapy),; Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)
Travel, Accommodations, Expenses - Amgen; Array BioPharma; AstraZeneca/MedImmune; Benevir; Bristol-Myers Squibb; Castle Biosciences; Checkmate Pharmaceuticals; EMD Serono; Gilead Sciences; IDEAYA Biosciences; Janssen; Jounce Therapeutics; Merck; Novartis; Reflexion Medical